Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05858879 · ClinicalTrials.gov registry record · NA

Notification of Incidental Coronary Artery Calcium in Patients With Atherosclerotic Cardiovascular Disease (NOTIFY-ASCVD)

A NA study of ASCVD and Coronary Artery Calcification, sponsored by Stanford University.

Active
Registry status
NA
Development phase
233
Enrollment target
1
Study location

NCT05858879: Active NA study of ASCVD and Coronary Artery Calcification, sponsored by Stanford University.

NCT05858879 is a NA study of ASCVD and Coronary Artery Calcification that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 233 participants, below the 13,405-participant average among 5 other ASCVD trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05858879, a NA study of ASCVD and Coronary Artery Calcification, is active but no longer recruiting, sponsored by Stanford University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
233 participants
Enrollment target
1
Study location

Study Summary

Estimate the impact of notifying both patients and their clinicians of the presence of incidental coronary artery calcium (CAC) on initiation of lipid-lowering therapy in patients with ASCVD who are not receiving lipid-lowering therapy.

Primary Outcome

Number of patients who had initiation of lipid-lowering therapy

Interventions

  • OTHER Notification of patients and clinicians

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 233 participants
Start Date 2024-10-22
Est. Completion 2026-09
Phase NA
Stanford University

1,744 total trials

What the registry record for NCT05858879 still lists

NCT05858879 is an interventional study that assigns participants to a tested intervention. The registered 233 participants enrollment target is mid-sized for trials with a published cap, below the 13,405-participant average among 5 other ASCVD trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with ASCVD appearing as the primary indexed condition, and to 1 intervention - of which Notification of patients and clinicians is the first listed.

NCT05858879 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05858879 about?

NCT05858879 is a clinical study titled "Notification of Incidental Coronary Artery Calcium in Patients With Atherosclerotic Cardiovascular Disease (NOTIFY-ASCVD)". Estimate the impact of notifying both patients and their clinicians of the presence of incidental coronary artery calcium (CAC) on initiation of lipid-lowering therapy in patients with ASCVD who are not receiving lipid-lowering therapy.

What is the current status of trial NCT05858879?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 233 participants. The study started on 2024-10-22. Estimated completion is 2026-09.

What conditions does trial NCT05858879 study?

This clinical trial studies the following conditions: ASCVD, Coronary Artery Calcification.

What interventions are being tested in trial NCT05858879?

The interventions under investigation include: Notification of patients and clinicians (OTHER).

Who is sponsoring clinical trial NCT05858879?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05858879 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ASCVD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06993844 · 233 participants · Phase 1

    Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

  • NCT07141706 · 233 participants · Phase 1

    A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

  • NCT04942717 · 234 participants · NA

    Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

  • NCT05208671 · 234 participants · NA

    Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05858879, the US trial registry maintained by the National Library of Medicine. NCT05858879 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.